<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159673">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797094</url>
  </required_header>
  <id_info>
    <org_study_id>191622-122</org_study_id>
    <nct_id>NCT01797094</nct_id>
  </id_info>
  <brief_title>BOTOX速 in the Treatment of Upper Facial Lines in Japan</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of BOTOX速 (botulinum toxin Type A) for the
      treatment of upper facial lines (Crow's Feet Lines and Frown Lines).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator's Assessment of the Severity of Crow's Feet Lines at Maximum Smile Using the Facial Wrinkle Scale</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Change in Appearance of Crow's Feet Lines as Measured by a 7-point Scale</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Appearance of Crow's Feet Lines as Measured by the Facial Line Outcomes Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Age-related Facial Appearance as Measured by the Self-Perception of Age Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Satisfaction with Treatment as Measured by the Facial Line Satisfaction Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Upper Facial Rhytides</condition>
  <condition>Crow's Feet Lines</condition>
  <condition>Glabellar Lines</condition>
  <condition>Frown Lines</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin Type A (44 U)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin Type A (32 U)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A (44 U)</intervention_name>
    <description>44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.</description>
    <arm_group_label>Botulinum toxin Type A (44 U)</arm_group_label>
    <other_name>BOTOX速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A (32 U)</intervention_name>
    <description>32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.</description>
    <arm_group_label>Botulinum toxin Type A (32 U)</arm_group_label>
    <other_name>BOTOX速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Moderate to severe Crow's Feet Lines and Frown Lines

        Exclusion Criteria:

          -  Current or previous botulinum toxin treatment of any serotype

          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis

          -  Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial
             peels, or topical retinoid therapy or hormone cream within 3 months

          -  Laser treatment or phototherapy of the face for medical purposes, blepharoplasty,
             brow-lift or related procedure, periorbital permanent make-up, or oral retinoid
             therapy within one year

          -  Medium-depth or deep facial peels within 5 years

          -  Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift,
             periorbital treatment with fillers, implantation or transplantation)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
